CSL

CSL Limited is one of the world's largest biotechnology companies by market capitalisation, built on more than a century of plasma science and vaccine development. Founded in 1916 as the Commonwealth Serum Laboratories in Melbourne, Australia, the company has grown from a government research body into a global ASX- and ADR-listed biotherapeutics group operating across more than 100 countries.

Plasma-Derived Therapies and Behring

The company's flagship division, CSL Behring, is among the world's leading manufacturers of plasma-derived therapies, supplying immunoglobulins, albumin, coagulation factors, and specialty products to patients with rare and serious conditions including primary immune deficiencies, haemophilia, and hereditary angioedema. CSL Behring operates one of the largest plasma collection networks globally, with hundreds of donation centres across North America and Europe, underpinning a manufacturing supply chain that processes tens of millions of litres of plasma each year.

Seqirus and Influenza Vaccine Leadership

CSL's second major division, Seqirus, is one of the two largest influenza vaccine producers in the world. Operating high-containment manufacturing facilities in the United Kingdom, the United States, and Australia, Seqirus supplies seasonal and pandemic influenza vaccines to governments and healthcare systems globally, including longstanding contracts with national immunisation programmes. The division's cell-based and adjuvanted vaccine technologies are recognised by public health authorities as meaningful advances over traditional egg-based manufacturing.

In 2022 CSL completed the acquisition of Vifor Pharma, a Swiss-headquartered specialist in iron deficiency, nephrology, and cardio-renal therapies, substantially expanding the group's product portfolio and its presence in hospital and renal care markets. CSL is headquartered in Melbourne, Australia, with major operational hubs in King of Prussia (Pennsylvania), Marburg (Germany), and Bern (Switzerland).

The group invests heavily in research and development, with a pipeline spanning recombinant therapies, gene therapy, and next-generation plasma fractionation. CSL's scale, century-long heritage in biologics manufacturing, and vertically integrated plasma network position it as a critical supplier to healthcare systems managing rare, chronic, and infectious disease.

Further information is available at csl.com.